Markets›NRIX

Nurix Therapeutics, Inc.

NRIX
23.01
-0.64 (-2.71%)
Closing price for Sep 25, 2026 from Polygon.io

Valuation

Market value2.39B
Price to earnings (P/E)Not meaningful (loss)
Price to sales65.0
Price to book5.9
Free cash flow yield-12.8%

Profitability (last 12 months)

Revenue36.77M
Net income-341.35M
Gross margin0.0%
Operating margin-982.4%
Net margin-928.4%
Return on equity-84.8%
Return on assets-63.7%

Growth (last fiscal year, FY 2025)

Revenue growth+54.0%

Balance sheet (latest quarter)

Cash and equivalents67.69M
Current ratio6.34

Per share and dividends

EPS, diluted (last 12 months)-3.46
Shares outstanding103.78M
Dividends paid (last 12 months)None

Trading

Price23.01
52-week high28.23
52-week low8.85
1-year price change+147.95%
Average volume (3 months)1.27M
Beta against the S&P 500 (1 year)1.43

Calculated from Nurix Therapeutics, Inc.'s SEC filings (latest quarter ending May 31, 2026) and the price above. "Last 12 months" adds up the four most recent quarters. Beta compares one year of daily returns with the S&P 500 (SPY). Dividends from Polygon.io or Nasdaq.